TY - JOUR
T1 - Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye
AU - Huu, Viet Anh Nguyen
AU - Luo, Jing
AU - Zhu, Jie
AU - Zhu, Jing
AU - Patel, Sherrina
AU - Boone, Alexander
AU - Mahmoud, Enas
AU - McFearin, Cathryn
AU - Olejniczak, Jason
AU - De Gracia Lux, Caroline
AU - Lux, Jacques
AU - Fomina, Nadezda
AU - Huynh, Michelle
AU - Zhang, Kang
AU - Almutairi, Adah
N1 - Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/2/28
Y1 - 2015/2/28
N2 - Therapies for macular degeneration and diabetic retinopathy require intravitreal injections every 4-8 weeks. Injections are uncomfortable, time-consuming, and carry risks of infection and retinal damage. However, drug delivery via noninvasive methods to the posterior segment of the eye has been a major challenge due to the eye's unique anatomy and physiology. Here we present a novel nanoparticle depot platform for on-demand drug delivery using a far ultraviolet (UV) light-degradable polymer, which allows noninvasively triggered drug release using brief, low-power light exposure. Nanoparticles stably retain encapsulated molecules in the vitreous, and can release cargo in response to UV exposure up to 30 weeks post-injection. Light-triggered release of nintedanib (BIBF 1120), a small molecule angiogenesis inhibitor, 10 weeks post-injection suppresses choroidal neovascularization (CNV) in rats. Light-sensitive nanoparticles are biocompatible and cause no adverse effects on the eye as assessed by electroretinograms (ERG), corneal and retinal tomography, and histology.
AB - Therapies for macular degeneration and diabetic retinopathy require intravitreal injections every 4-8 weeks. Injections are uncomfortable, time-consuming, and carry risks of infection and retinal damage. However, drug delivery via noninvasive methods to the posterior segment of the eye has been a major challenge due to the eye's unique anatomy and physiology. Here we present a novel nanoparticle depot platform for on-demand drug delivery using a far ultraviolet (UV) light-degradable polymer, which allows noninvasively triggered drug release using brief, low-power light exposure. Nanoparticles stably retain encapsulated molecules in the vitreous, and can release cargo in response to UV exposure up to 30 weeks post-injection. Light-triggered release of nintedanib (BIBF 1120), a small molecule angiogenesis inhibitor, 10 weeks post-injection suppresses choroidal neovascularization (CNV) in rats. Light-sensitive nanoparticles are biocompatible and cause no adverse effects on the eye as assessed by electroretinograms (ERG), corneal and retinal tomography, and histology.
KW - Anti-angiogenic
KW - Light-triggered
KW - Nanoparticle
KW - Ocular
KW - Polymer
KW - Triggered release
UR - http://www.scopus.com/inward/record.url?scp=84920747606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920747606&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2015.01.001
DO - 10.1016/j.jconrel.2015.01.001
M3 - Article
C2 - 25571784
AN - SCOPUS:84920747606
SN - 0168-3659
VL - 200
SP - 71
EP - 77
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -